KURAKura Oncology, Inc.
Pharmaceutical Preparations
- Revenue
- $67M
- 25% YoY
- Operating margin
- -449.9%
- 25% YoY
- EBITDA
- −$303M
- 57% YoY
- Market cap
- $913M
- Employees
- 260
- $260K revenue each
- Net debt / EBITDA
- —
- −$61M net debt
- AI in 10-K
- 0.2
- mentions per 10K words
Takeover score 4 of 13
Fixable underperformance 2 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$5M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCYes55% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentYes66% lowest supportAny vote under 80% support
Buyer economics 2 of 4
- Low revenue per employeeNo$260K · 40th pctBottom quartile of its SIC industry
- Quiet on AIYes0.2 per 10K words · 13th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$913M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$1M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $54M | $67M | 25% |
| Operating income | — | −$140M | −$166M | −$193M | −$304M | 57% |
| Net income | −$130M | −$136M | −$153M | −$174M | −$279M | 60% |
| Operating cash flow | −$105M | −$110M | −$125M | $134M | −$64M | 148% |
| Capex | $1M | $626K | $168K | $472K | $7M | 1306% |
| Stock-based comp | $24M | $26M | $28M | $34M | $37M | 9.5% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $2M · 2
- Open-market sells, 12 mo
- $4M · 40
- Net
- −$1M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $6M | 84 | — |
| FY2024 | $6M | $4M | 70 | — |
| FY2023 | $5M | $6M | 116 | — |